Humacyte, Inc.

NASDAQ:HUMA

Biotechnology

Healthcare
$0.50 -3.35%

-$0.03 today

Market cap
$138.90M
Beta
2.46
P/E (TTM)
-1.9
EPS (TTM)
-$0.49
52W Low $0.55High $2.84

Volume 3.91M

Average 8.14M

HUMA Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Humacyte, Inc.NASDAQ: HUMA

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns positive

Q1 FY2026 accounts receivables was $7K, compared with -$308K a year earlier. Trailing-twelve-month accounts receivables was $54K.

Context

  • Accounts receivables amounted to 12.8% of revenue in FY2025.
  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $7K or moves back toward the trailing-twelve-month quarterly average of $13.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7K-98.9% QoQ
Last fiscal yearDec 2025
-$261K— YoY
LTMMar 2026
$54K+117.5% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+102.3%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(261K) USD
Year-over-year change
—

Accounts Receivables vs competitors

How HUMA compares with its peers on the latest reported figures

  • HUMA's LTM Mar 2026 accounts receivables of $54K is the 5th largest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of +117.5% is the highest of 5, against a peer median of -29.4%.
  • Accounts receivables amounts to 2.7% of revenue for HUMA, versus a peer median of 5.7%.
HUMA Competitors Peer median
Accounts Receivables for HUMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$13.31M +6.6%—29.4%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$12.33M +56.3%+89.9%5.7%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$1.26M -98.3%—21.9%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$465K -65.5%-17.4%1.3%
HUMAHumacyte, Inc.LTM Mar 2026$54K +117.5%—2.7%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$0 ———
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$0 ———
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 ———
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$0 ———
IMRXImmuneering CorporationLTM Mar 2026$0 ———
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding HUMA) $0-29.4%+36.3%5.7%

Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Depreciation & Amortization8.24M8.21M7.72M7.19M5.33M
Deferred Income Tax00000
Stock-Based Compensation10.15M6.18M6.83M6.14M9.75M
Change in Working Capital(557K)1.03M6.57M311K(23.4M)
Accounts Receivables(63K)145K31K0(261K)
Inventory0000(21.83M)
Accounts Payables(197K)(509K)4.81M(1.96M)973K
Other Working Capital(297K)1.39M1.73M2.27M(2.28M)
Other Non-Cash Items(72.54M)(74.59M)16.35M36.94M(55.9M)
Operating Cash Flow(81.19M)(71.13M)(73.31M)(98.12M)(105.04M)
Capital Expenditures(220K)(1.05M)(2.28M)(1.57M)(884K)
Acquisitions (Net)00000
Purchases of Investments(8M)(10.11M)000
Sales of Investments016M2.11M00
Other Investing Activities00000
Investing Cash Flow(8.22M)4.85M(173K)(1.57M)(884K)
Debt Repayment27.93M(1.98M)5.7M(2.58M)36.39M
Common Stock Issued598K535K566K45.93M113.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities239.05M535K(1.76M)27.71M(88.34M)
Financing Cash Flow266.98M(1.45M)4.51M114.18M61.49M
Effect of Forex Changes00(209K)00
Net Change in Cash177.57M(67.73M)(69.18M)14.49M(44.44M)
Free Cash Flow(81.41M)(72.18M)(75.59M)(99.69M)(105.93M)

Humacyte, Inc.

NASDAQ:HUMA

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.